Catalyst Pharma (CN2) Stock Statistics & Valuation Metrics

Catalyst Pharma has a market cap or net worth of CHF3.11B. The enterprise value is $3.09B.

Catalyst Pharma has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Catalyst Pharma’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 20.30%.

The current PE Ratio of Catalyst Pharma is 17.5. Catalyst Pharma’s PEG ratio is 0.50.

In the last 12 months, Catalyst Pharma had revenue of 588.99M and earned 214.33M in profits. Earnings per share was 1.75.

In the last 12 months, operating cash flow was 208.21M and capital expenditures -85.00K, giving a free cash flow of 208.13M billion.

Catalyst Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Catalyst Pharma upcoming earnings date is Aug 12, 2026, After Close (Confirmed).

Catalyst Pharma as a current ratio of 6.08, with Debt / Equity ratio of 0.26%

In the past 12 months, Catalyst Pharma has paid 69.19M in taxes.

Catalyst Pharma EV to EBITDA ratio is 6.68, with an EV/FCF ratio of 10.30.

Catalyst Pharma has CHF755.86M in cash and marketable securities with CHF2.68M in debt, giving a net cash position of CHF753.18M billion.

Gross margin is 82.32%, with operating margin of 43.77%, and net profit margin of 36.39%.

The average price target for Catalyst Pharma is CHF25.92, which is 11.43% higher than the current price. The consensus rating is Moderate Buy